Globeflex Capital L P Buys Shares of 145,917 Xeris Biopharma Holdings, Inc. $XERS

Globeflex Capital L P purchased a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 145,917 shares of the company’s stock, valued at approximately $1,156,000. Globeflex Capital L P owned about 0.08% of Xeris Biopharma as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Kestra Advisory Services LLC bought a new stake in shares of Xeris Biopharma in the fourth quarter worth $25,000. KBC Group NV bought a new position in Xeris Biopharma in the first quarter valued at $27,000. Allworth Financial LP acquired a new stake in Xeris Biopharma in the 2nd quarter valued at $34,000. State of Wyoming acquired a new stake in Xeris Biopharma in the 2nd quarter valued at $52,000. Finally, Caitong International Asset Management Co. Ltd lifted its position in Xeris Biopharma by 9,276.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after buying an additional 7,421 shares in the last quarter. 42.75% of the stock is owned by institutional investors.

Insider Transactions at Xeris Biopharma

In other news, insider Kevin Mcculloch sold 15,000 shares of Xeris Biopharma stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $8.02, for a total transaction of $120,300.00. Following the completion of the transaction, the insider directly owned 1,676,126 shares in the company, valued at approximately $13,442,530.52. The trade was a 0.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 16,666 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $8.01, for a total value of $133,494.66. Following the transaction, the insider directly owned 1,144,462 shares in the company, valued at $9,167,140.62. The trade was a 1.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 271,499 shares of company stock valued at $2,038,917. Company insiders own 4.35% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Wall Street Zen downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Barclays upped their target price on Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $12.00.

Xeris Biopharma Stock Performance

Shares of XERS stock opened at $8.74 on Tuesday. The stock has a market cap of $1.59 billion, a P/E ratio of -79.45 and a beta of 0.66. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. The company has a fifty day moving average price of $8.15 and a two-hundred day moving average price of $6.88. Xeris Biopharma Holdings, Inc. has a one year low of $5.25 and a one year high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%.The firm had revenue of $92.10 million for the quarter, compared to analyst estimates of $90.12 million. As a group, equities analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current year.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.